Can pulmonary atresia be treated after 15 years

Agicagrelor versus prasugrel in diabetics: a pharmacodynamic study

Eligibility to participate


Inclusion criteria: - Age 18 to 75 years - Diabetics who were treated with oral and / or parenteral hypoglycemic therapy for at least 1 month - Patients with acute coronary syndrome who underwent PCI with a basic PR assessment 24 hours after PCI with clopidogrel - Declaration of consent obtained in writing Exclusion criteria: - Treatment with other test equipment (including placebo) or devices within 30 years of the randomization or planned use of test equipment or devices prior to the day 30 visit. - Pregnancy - Breastfeeding - Inability to give informed consent or high probability of not being available for the day 30 of follow-up. - Cardiogenic shock - Serious periprocedural complications (death, stent thrombosis, vascular perforation, arrhythmias that require cardioversion, temporary introduction of a cardiac pacemaker or intravenous administration) Antiarrhythmics, respiratory failure requiring intubation, vascular injury (pseudo-aneurysm, retro-venio-nerve or arterial hemorrhage) the arterial catheter insertion site), profuse bleeding (need for a blood transfusion or decrease in hemoglobin after PCI by ≥ 5 g / dl or intracranial bleeding) - unsuccessful PCI (residual stenosis> 30% or flow <ΤΙΜΙ 3) or planned staged PCI in the next 30 days after randomization - Request an oral anticoagulant before the visit on day 30 - Current or planned therapy with other ADP receptor inhibitors of the thienopyridine class - Known hypersensitivity to prasugrel or ticagrelor - History of gastrointestinal bleeding, urogeni bleeding from the valley or other abnormal areas of bleeding within the last 6 months. - Other bleeding diatheses or bleeding classified as at risk by the examiner during long-term therapy with thienopyridine. - Any history of ischemic stroke, intracranial hemorrhage, or disease (neoplasm, arteriovenous malformation, aneurysm). - Thrombocytopenia (<100,000 / μl) if randomized - Anemia (Hct <30%) if randomized - Polycytemia (Hct> 52%) if randomized - Administration of periprocedural IIb / IIIa inhibitors - Severe allergy to contrast media, unfractionated heparin, enoxaparin or Bivalirudin that cannot be sufficiently predicted. - Recent (<6 weeks) major surgery or trauma, including GABG. - Subjects who are treated daily with nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors who cannot be discontinued for the duration of the study. - Concomitant oral or intravenous therapy with strong CY P3A inhibitors (ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazana vir, grapefruit juice with narrow / A Cyclosporine, quinidine) or strong CYP3A inducers (rifampin / rifampicin, phenytoin, carbamazepine). - Increased risk of bradycardial events. - Dialysis required. - Age ≥ 75 years - Weight <60 kg - Severe liver dysfunction - Severe uncontrolled chronic obstructive pulmonary disease



Minimum age:

18 years

Maximum age:

75 years

Healthy volunteers: